ECTRIMS 2021 | VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS

Robert Glanzman, MD, FAAN, Clene Inc., Salt Lake City, UT, shares an overview of the ongoing VISIONARY-MS trial, assessing CNM-Au8 as a novel disease-modifying therapy (DMT) in patients with stable relapsing-remitting multiple sclerosis (MS). The aqueous suspension of pure gold nanocrystals is under investigation as a remyelinating treatment for chronic optic neuropathy in MS. Participants of the Phase II randomized, placebo-controlled trial will be treated with CNM-Au8 or placebo as an add-on to their current treatment regimen. CNM-Au8 has the potential to target progression independent of relapse activity, an area where effective treatments are lacking. Enrollment is ongoing and aims to be completed in 2022. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.